Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
This DSIR recognition for company's in-house R&D Unit make it eligible for receiving funds for R&D purpose from various government departments and agencies
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
The company will respond to these observations within the stipulated time period.
The hospital will have all the modern facilities like modular OT, state of the art medical equipment, labs, etc. It will have OPD and IPD services
APAC to see a reduction in imported surgical robotics
Under the soon to be launched Heal in India initiative, India aims to provide its health infrastructure for patients abroad and make it a global hub for medical and value-based healthcare for patients from across the world
Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient and finished drug at its facilities approved by USFDA
Subscribe To Our Newsletter & Stay Updated
